Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients.

By Y. Miyazaki, Archana Mahankali, M. Matsuda, S. Mahankali, Jean Hardies, K. Cusi, Lawrence J. Mandarino, Ralph DeFronzo. Journal of Clinical Endocrinology and Metabolism, 2002

743 citations recorded by the source corpus.

Subfields: Epidemiology, Physiology

View Paper: https://www.semanticscholar.org/paper/4dcd42d8639cc56dd8b8f1ab0955284f130404b2

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Epidemiology

1. Ralph DeFronzo
2. André Tchernof
3. V. Samuel
4. Gerald I. Shulman
5. Alexander Sakers
6. J. Despres
7. C. R. Kahn
8. Mirian Krystel De Siqueira

In Physiology

1. Ralph DeFronzo
2. Gerald I. Shulman
3. V. Samuel
4. Alexander Sakers
5. J. Despres
6. C. R. Kahn
7. Mirian Krystel De Siqueira
8. Lawrence J. Mandarino

Citations in the corpus

• Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture 2009 (2010, background): “Thiazolidinediones, insulin sensitivity and NEFA metabolism Thiazolidinediones are potent insulin sensitisers in muscle and liver [126, 127, 140, 141, 172, 173] and improve sensitivity to the antilipolytic effect of insulin, decreasing basal NEFA turnover/plasma NEFA [172].”
• Adipose Tissue Distribution, Inflammation and Its Metabolic Consequences, Including Diabetes and Cardiovascular Disease (2020, background): “Activation of PPARγ by TZDs not only enhances adipogenesis, it also alleviates inflammatory cytokine secretion associated with obesity (649) and reduces ectopic fat deposition in tissues such as the liver and skeletal muscle (650).”
• Adipose tissue plasticity in health and disease (2022, background): “Visceral adipose tissue is more prone to immune cell infiltration and inflam-matory cytokine production than SAT, especially in obesity (Item and Konrad, 2012).”
• Non-Alcoholic Fatty Liver Disease as a Nexus of Metabolic and Hepatic Diseases (2017, positive): “TZDs decrease ectopic lipid accumulation (Mayerson et al., 2002), decrease visceral adipose tissue mass (Miyazaki et al., 2002; Mori et al., 1999), and improve hepatic and muscle insulin resistance (Mayerson et al., 2002; Petersen et al., 2000; Tonelli et al., 2004).”
• Abdominal obesity and metabolic syndrome (2006, neutral): “In accordance with this hypothesis, treatment with glitazones increases subcutaneous fat depositio”
• Beneficial effects of subcutaneous fat transplantation on metabolism. (2008, result): “This notion is also consistent with the effects of thiazolidinedione treatment, which improves insulin sensitivity despite increasing total body fat mass by primarily increasing the subcutaneous fat depot (Miyazaki et al., 2002).”